A Phase 2 interventional study of OPK-88003 and Placebo in Type 2 Diabetes Mellitus, sponsored by OPKO Health, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-15.
Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,321st largest by enrollment of the 2,960 interventional ones that give a count, is one of 126 that started in 2018, is one of 391 in phase 2, and was the 2,043rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 126 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,960 interventional studies, 128 across the 336 observational. Of the 2,650 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,307 have an industry lead sponsor. The 10 most frequent:
OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
OPKO Health, Inc. has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
189 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 189 to your calendar (.ics) → With an account.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.
This clinical trial is a phase 2, double-blind dose escalation regimen of once-weekly OPK-88003 in subjects with T2DM. The trial consists of a screening/baseline (up to 2 weeks prior to first dose), treatment period consisting of a dose escalation (8 weeks) and a target dose (22 weeks), and a follow-up period (4 weeks). Subjects will be randomly assigned to volume-matched OPK-88003 or placebo administered QW.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
Drug: Placebo
70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
Drug: OPK-88003
OPK-88003 subcutaneous injection
Placebo subcutaneous injection
Change in HbA1c in Subjects With Type 2 DM
To evaluate the effect of dose escalation of QW SC OPK-88003 vs placebo injections on HbA1c absolute change from baseline to after 30 weeks treatment in subjects with T2DM inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.
Time frame: From baseline to 30 weeks
Mean Percent (%) Body Weight Change
Mean percent (%) body weight change from baseline to after 30 weeks treatment
Time frame: From baseline to 30 weeks
Percent (%) of Subjects With 5% or Greater Body Weight Loss.
Percent (%) of subjects with 5% or greater body weight loss after 30 weeks treatment
Time frame: 30 weeks.
Change From Baseline of Fasting Plasma Glucose (FPG).
Change of FPG from baseline to after 30 weeks treatment
Time frame: 30 weeks.
| Milestone | Placebo | OPK-88003 |
|---|---|---|
| Started | 41 | 72 |
| Completed | 25 | 51 |
| Not completed | 16 | 21 |
To evaluate the effect of dose escalation of QW SC OPK-88003 vs placebo injections on HbA1c absolute change from baseline to after 30 weeks treatment in subjects with T2DM inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.
| mmols/mol | Placebo | OPK-88003 |
|---|---|---|
| Change in HbA1c in Subjects With Type 2 DM | -0.25 ± 0.209 | -1.47 ± 0.168 |
Mean percent (%) body weight change from baseline to after 30 weeks treatment
| Percentage of body weight change | Placebo | OPK-88003 |
|---|---|---|
| Mean Percent (%) Body Weight Change | -2.10 ± 0.976 | -5.83 ± 0.737 |
Percent (%) of subjects with 5% or greater body weight loss after 30 weeks treatment
| Percentage of participants | Placebo | OPK-88003 |
|---|---|---|
| Percent (%) of Subjects With 5% or Greater Body Weight Loss. | 16.7 | 48.8 |
Change of FPG from baseline to after 30 weeks treatment
| mg/dL | Placebo | OPK-88003 |
|---|---|---|
| Change From Baseline of Fasting Plasma Glucose (FPG). | -13.3 ± 7.04 | -46.2 ± 5.86 |
Collected over 36 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/41 (0%) | 2/41 (4.9%) | 5/41 (12.2%) |
| OPK-88003 | 0/72 (0%) | 9/72 (12.5%) | 35/72 (48.6%) |
| Event | Placebo | OPK-88003 |
|---|---|---|
| Cecal volvulus s/p right hemicolectomyGastrointestinal disorders | 1/41 | 0/72 |
| SepsisInfections and infestations | 1/41 | 0/72 |
| Acute toxic encephalopathyNervous system disorders | 1/41 | 0/72 |
| Branch retinal artery occlusionEye disorders | 0/41 | 1/72 |
| Branch retinal artery occlusion account for peripheral vision loss right eyeEye disorders | 0/41 | 1/72 |
| Acute cholelithiasisHepatobiliary disorders | 0/41 | 1/72 |
| Acute pancreatitisGastrointestinal disorders | 0/41 | 1/72 |
| Coronary artery diseaseCardiac disorders | 0/41 | 1/72 |
| Hypersensitivity reactionImmune system disorders | 0/41 | 1/72 |
| Systemic inflammatory response syndromeGeneral disorders | 0/41 | 1/72 |
| Event | Placebo | OPK-88003 |
|---|---|---|
| NauseaGastrointestinal disorders | 2/41 | 28/72 |
| VomitingGastrointestinal disorders | 1/41 | 19/72 |
| DiarrhoeaGastrointestinal disorders | 3/41 | 9/72 |
| Lipase increasedInvestigations | 0/41 | 2/72 |
| Acute myocardial infarctionCardiac disorders | 0/41 | 1/72 |
| Abdominal pain upperGastrointestinal disorders | 0/41 | 1/72 |
| Pancreatitis acuteGastrointestinal disorders | 0/41 | 1/72 |
| RetchingGastrointestinal disorders | 0/41 | 1/72 |
| Drug hypersensitivityImmune system disorders | 0/41 | 1/72 |
| HypersensitivityImmune system disorders | 0/41 | 1/72 |
| Age, Continuous(Year) | Placebo | OPK-88003 | Total |
|---|---|---|---|
| Mean | 57.4 ± 9.06 | 53.8 ± 9.94 | 55.1 ± 9.75 |
| Sex: Female, Male(Participants) | Placebo | OPK-88003 | Total |
|---|---|---|---|
| Female | 24 | 29 | 53 |
| Male | 17 | 43 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | OPK-88003 | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 36 | 59 |
| Not Hispanic or Latino | 18 | 36 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | OPK-88003 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 12 | 18 |
| White | 33 | 60 | 93 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2018 to primary completion in Mar 2019, 11 months.
Results were first posted in Jun 2021, 2 years 3 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.